Physician profile
Suzanne Hall
NPI 1356741334
$1,476.73
in general payments reported to CMS, 2019-2025
27 companies · $20.00 in 2025
The $20.00 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $678 · 2022: $549 · 2023: $104 · 2024: $125 · 2025: $20.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $138 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $137.77 |
| Education | $111.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $158.92 | 2021-2022 | |
| Amgen INC. | $148.42 | 2021-2022 | |
| Aveo Pharmaceuticals, INC. | $141.04 | 2022-2025 | |
| Seagen INC. | $118.68 | 2021 | |
| Abbvie INC. | $116.43 | 2021-2022 | |
| Coloplast Corp | $103.94 | 2023 | Sensura Mio |
| Genentech USA, INC. | $102.45 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $95.00 | 2021 | |
| Lundbeck LLC | $79.93 | 2021-2022 | |
| Genzyme Corporation | $57.24 | 2021-2022 | |
| Sage Therapeutics, LLC | $33.83 | 2024 | |
| Celgene Corporation | $31.12 | 2022 | |
| Lilly USA, LLC | $31.04 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $29.72 | 2021-2022 | |
| Incyte Corporation | $28.89 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $23.91 | 2022 | |
| Alexion Pharmaceuticals, INC. | $23.74 | 2021 | |
| Apellis Pharmaceuticals, INC. | $22.60 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.79 | 2021 | |
| Dova Pharmaceuticals | $16.32 | 2021 | |
| Merck Sharp & Dohme LLC | $15.96 | 2021 | |
| Pfizer INC. | $15.13 | 2022 | |
| Gilead Sciences, INC. | $13.74 | 2021 | |
| Janssen Biotech, INC. | $13.62 | 2021 | |
| Puma Biotechnology, INC. | $12.87 | 2022 | |
| Beigene USA, INC. | $11.71 | 2021 | |
| Array Biopharma INC | $11.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.